Table 2 Safety variables
|  | EFJ (N = 103) [%] | VC (N = 98) [%] | P value |
|---|---|---|---|
Adverse events (AEs) | 76 [73.8%] | 105 [107.1%] | 0.016 |
Patients with AEs | 51 [49.5%] | 45 [45.9%] | 0.672 |
Adverse drug reactions | 3 [2.9%]a | 2 [2.0%]b | 1.000 |
AEs causing study termination | 0 [0%] | 2 [2.0%]c | 0.236 |
Serious adverse events (SAE) | 1 [1.0%]d | 1 [1.0%]e | 1.000 |